TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01632605
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
Study: NCT01953081
Drug: TD-8954
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01953081
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00450086
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 9 mg per day
Study: NCT00450086
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 g per day
Study: NCT00456729
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01666691
Drug: Beloranib
Normalized name: Beloranib
DrugBank: Beloranib (DB12671)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
Study: NCT01840540
Drug: Arterial infusion of autologous mesenchymal stem cells
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01161316
Drug: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.
Study: NCT02848339
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin desensitization
Study: NCT03051087
Drug: Ganirelix acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01413841
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 l oxygen
Study: NCT01413841
Drug: Regular nasal air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 l nasal air
Study: NCT01722487
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
Study: NCT01722487
Drug: Chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
Study: NCT02581111
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone 8-mg IV bolus
Study: NCT00190983
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
Study: NCT00637715
Drug: Alfuzosin
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01161316
Drug: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.
Study: NCT00949351
Drug: Aliskiren 300mg/d
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 300mg/d v.s. placebo for 12wk
Study: NCT03044379
Drug: Dapivirine gel (0.05%)
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
Study: NCT01844830
Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasally administered regional anesthetic
Study: NCT00522275
Drug: lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
Study: NCT01507168
Drug: GC33
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1600 mg iv Day 1 and 8, and every 2 weeks thereafter
Study: NCT03030300
Drug: Novolin 30R;Pioglitazone;Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone.
Study: NCT02300220
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg, twice daily for 1 week (oral)
Study: NCT02432248
Drug: Dehydroepiandrosterone
Normalized name: Dehydroepiandrosterone
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/day, PO for 90 days
Study: NCT01412008
Drug: Botox (botulinum toxin)
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
Study: NCT03336619
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 600 mg administered orally twice daily for five days
Study: NCT03337152
Drug: primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
Study: NCT03337152
Drug: chloroquine + primaquine
Normalized name: chloroquine / primaquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
Study: NCT00077610
Drug: Epoetin alfa or beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: intravenously 3 times weekly for 52 weeks, as prescribed
Study: NCT00077610
Drug: RO0503821 (1x/2 Weeks)
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
Study: NCT00077610
Drug: RO0503821 (1x/4 Weeks)
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
Study: NCT00240552
Drug: fosamprenavir
Normalized name: Fosamprenavir
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04109872
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
Study: NCT01436994
Drug: carbimazole
Normalized name: Carbimazole
DrugBank: Carbimazole (DB00389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
Study: NCT01436994
Drug: propylthiouracil
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
Study: NCT01436994
Drug: thyroxine
Normalized name: Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
Study: NCT02019394
Drug: Lu AE58054
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10.
Study: NCT03977220
Drug: Nab-paclitaxel combined with S-1
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
Study: NCT00553137
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg (5 tablets of 150 mg tablets)taken once
Study: NCT00553137
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg fluconazole tablets once daily for 14 days
Study: NCT02439944
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02439944
Drug: Nicotine mouthspray
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00216177
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remicade
Study: NCT00216177
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humira
Study: NCT00605410
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 puffs (40 micrograms) 2 puffs (0micrograms)
Study: NCT04202653
Drug: ETV
Normalized name: Metvixia
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: entecavir 0.5 mg qd
Study: NCT04202653
Drug: TQ-A3334
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-A3334 po qw
Study: NCT04202653
Drug: TQ-B2450
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-B2450 q3w iv
Study: NCT04741334
Drug: antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure to antiplatelet drugs
Study: NCT04474119
Drug: KN046
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
Study: NCT01589055
Drug: Intravenous Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
Study: NCT00234416
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00234416
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02235987
Drug: octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
Study: NCT00119730
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given on days 1-3 of each 28-day cycle
Study: NCT00119730
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given on day 1 of each 28-day cycle
Study: NCT00119730
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given on day 1 of each 28-day cycle
Study: NCT00119730
Drug: Zevalin
Normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
Study: NCT01961843
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
Study: NCT01961843
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
Study: NCT02072720
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
Study: NCT01999946
Drug: Extended-Release Naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
Study: NCT00448916
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Orally-administered pregabalin
Study: NCT00900913
Drug: ropivacaine (Naropin)
Normalized name: ropivacaine Injection [Naropin]
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion 1 mg/kg bw
Study: NCT00118508
Drug: risedronate (including placebo)
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: risedronate 35mg weekly
Study: NCT01248338
Drug: metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily 50 or 100 mg for one year
Study: NCT01248338
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily 5 mg capsule for one year
Study: NCT02365584
Drug: lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
Study: NCT01973452
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00819585
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab was supplied in glass vials as a lyophilized powder.
Study: NCT00819585
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg capsule orally once daily for 16 weeks.
Study: NCT00819585
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-300 mg orally once daily for 24 weeks.
Study: NCT00819585
Drug: Placebo Matching Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection.
Study: NCT00819585
Drug: Placebo Matching Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule orally once daily for 16 weeks.
Study: NCT01471704
Drug: INX-08189 50 mg
Normalized name: DNA (RECOMBINANT LENTIVIRUS VECTOR INXN-2004-TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
DrugBank: Dabocemagene autoficel (DB17878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Day 0: Single 50 mg dose of INX-08189 in the morning
Study: NCT01471704
Drug: 240 mg verapamil HCL ER
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
Study: NCT01471704
Drug: 50 mg dose of INX-08189 and 240 mg verapamil HCL ER
Normalized name: verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
Study: NCT02176291
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
Study: NCT03334396
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT02547116
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of Rifampin to standard anti-Staphylococcal treatment regimen
Study: NCT00012012
Drug: Amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
Study: NCT00012012
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
Study: NCT01858610
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01858610
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02089620
Drug: Yasmin
Normalized name: Yasmin
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will be used every 21 days for three months by the patient
Study: NCT02084784
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
Study: NCT02084784
Drug: methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
Study: NCT00028561
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00028561
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01814683
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
Study: NCT01814683
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
Study: NCT00048399
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00048399
Drug: FK506
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02178293
Drug: Benzidamine hydrochloride
Normalized name: benzydamine
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02568345
Drug: sugammadex ED90
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.